Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

被引：136
|
作者：
Kappel, Ben A. [1 ]
Lehrke, Michael [1 ]
Schutt, Katharina [1 ]
Artati, Anna [2 ]
Adamski, Jerzy [2 ,3 ,4 ]
Lebherz, Corinna [1 ]
Marx, Nikolaus [1 ]
机构：
[1] Rhein Westfal TH Aachen, Univ Hosp Aachen, Dept Internal Med 1, Pauwelsstr 30, D-52074 Aachen, Germany
[2] German Res Ctr Environm Hlth, Helmholtz Zentrum Muchen, Genome Anal Ctr, Inst Expt Genet, Neuherberg, Germany
[3] Tech Univ Munich, Life & Food Sci Ctr Weihenstephan, Inst Expt Genet, Freising Weihenstephan, Germany
[4] German Ctr Diabet Res, Neuherberg, Germany
来源：
CIRCULATION | 2017年 / 136卷 / 10期
关键词：
branched-chain amino acids; cardiovascular disease; empagliflozin; ketone bodies; metabolomics; SGTL2; inhibitors; type 2 diabetes mellitus; OUTCOMES;
D O I：
10.1161/CIRCULATIONAHA.117.029166
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：969 / 972
页数：4
相关论文
共 50 条
  • [1] Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
    Eliasson, Bjorn
    Ekelund, Jan
    Amberntsson, Rikard
    Miftaraj, Mervete
    Svensson, Ann-Marie
    DIABETES THERAPY, 2019, 10 (04) : 1523 - 1530
  • [2] Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease
    Monteiro, Pedro
    Aguiar, Carlos
    Matos, Pedro
    Silva-Nunes, Jose
    Birne, Rita
    Branco, Patricia
    Calado, Joaquim
    Melo, Miguel
    Polonia, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2019, 38 (10) : 721 - 735
  • [3] Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
    Fitchett, David
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    van de Borne, Philippe
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    George, Jyothis T.
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (03) : 364 - 367
  • [4] Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Yaribeygi, Habib
    Maleki, Mina
    Sathyapalan, Thozhukat
    Jamialahmadi, Tannaz
    Sahebkar, Amirhossein
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (25) : 2850 - 2863
  • [5] Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
    Björn Eliasson
    Jan Ekelund
    Rikard Amberntsson
    Mervete Miftaraj
    Ann-Marie Svensson
    Diabetes Therapy, 2019, 10 : 1523 - 1530
  • [6] Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
    Zinman, Bernard
    Inzucchi, Silvio E.
    Lachin, John M.
    Wanner, Christoph
    Fitchett, David
    Kohler, Sven
    Mattheus, Michaela
    Biomath, Dipl
    Woerle, Hans J.
    Broedl, Uli C.
    Johansen, Odd Erik
    Albers, Gregory W.
    Diener, Hans Christoph
    STROKE, 2017, 48 (05) : 1218 - +
  • [7] Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease
    Anker, Stefan D.
    Sander, Leif-Erik
    Fitchett, David H.
    Zinman, Bernard
    Ofstad, Anne Pernille
    Wanner, Christoph
    Vedin, Ola
    Lauer, Sabine
    Verma, Subodh
    Yaggi, Henry K.
    Inzucchi, Silvio E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [8] Effect of empagliflozin in peripheral diabetic neuropathy of patients with type 2 diabetes mellitus
    El-Haggar, Sahar Mohamed
    Hafez, Yasser Mostafa
    El Sharkawy, Amira Mohamed
    Khalifa, Maha
    MEDICINA CLINICA, 2024, 163 (02): : 53 - 61
  • [9] Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
    Anderson, John E.
    Wright, Eugene E., Jr.
    Shaefer, Charles F., Jr.
    DIABETES THERAPY, 2017, 8 (01) : 33 - 53
  • [10] Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
    Ramos, Mafalda
    Men, Peng
    Wang, Xu
    Ustyugova, Anastasia
    Lamotte, Mark
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
12345